Related Experiment Video
Updated: Feb 5, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
The CKD plasma lipidome varies with disease severity and outcome
Flore Duranton1, Jonas Laget2, Nathalie Gayrard1
1RD-Néphrologie, Montpellier, France; BC2M, Univ Montpellier, Montpellier, France.
Insights
Lipid levels, including lysophosphatidylcholines (LPCs), are reduced in hemodialysis patients with chronic kidney disease (CKD). Lower LPC levels are linked to a higher risk of adverse outcomes in CKD patients.
Area of Science:
- Biochemistry
- Nephrology
- Metabolomics
Background:
- Chronic kidney disease (CKD) is associated with significant alterations in lipid metabolism.
- Understanding these metabolic changes is crucial for managing patient outcomes.
Purpose of the Study:
- To quantify lipid species in plasma from CKD and hemodialysis (HD) patients.
- To investigate the association between lipid profiles, CKD severity, and patient prognosis.
Main Methods:
- Plasma samples from 77 CKD patients (stages 2-HD) were analyzed for phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), sphingomyelins (SMs), and fatty acids.
- Lipid levels were measured using mass spectrometry and gas chromatography.
- Statistical analyses included Kruskal Wallis tests and Cox regressions.
Main Results:
- HD patients showed decreased plasma levels of PCs, LPCs, and SMs compared to non-dialyzed CKD patients.
- Thirty-four lipids were less abundant in HD patients; elaidic acid levels were increased.
- Higher total LPCs and specific LPCs (LPC 18:2, LPC 20:3) correlated with a better patient outcome.
Conclusions:
- Hemodialysis patients exhibit reduced plasma lipid concentrations, particularly LPCs.
- Decreased LPC levels are associated with an increased risk of adverse events in CKD.
- Observed lipid alterations may indicate underlying metabolic dysfunctions in CKD and HD patients.
Background:
Various alterations in lipid metabolism have been observed in patients with chronic kidney disease (CKD).
Objectives:
To determine the levels of lipid species in plasma from CKD and hemodialysis (HD) patients and test their association with CKD severity and patient outcome.
Methods:
Seventy-seven patients with CKD stage 2 to HD were grouped into classes of CKD severity at baseline and followed-up for 3.5 years for the occurrence of transition to HD or death (combined outcome). Plasma levels of phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs), sphingomyelins (SMs), and fatty acids were analyzed by flow-injection analysis coupled to tandem mass spectrometry or gas chromatography coupled with mass spectrometry. Kruskal Wallis rank tests and Cox regressions were used to analyze the association of lipids with CKD severity and the risk of combined outcome, respectively.
Results:
The plasma level of PCs, LPCs, and SMs was decreased in HD patients compared with nondialyzed CKD patients (all P < .05), whereas esterified and/or nonesterified fatty acids level did not change. Thirty-four lipids displayed significantly lower abundance in plasma of HD patients, whereas elaidic acid (C18:1ω9t) level was increased (P < .001). The total amount of LPCs and individual LPCs were associated with better outcome (P < .05). In particular, LPC 18:2 and LPC 20:3 were statistically associated with outcome in adjusted models (P < .05).
Discussion:
In HD patients, a reduction in plasma lipids is observed. Some of the alterations, namely reduced LPCs, were associated with the risk of adverse outcome. These changes could be related to metabolic dysfunctions.
Related Concept Videos
Gradually Varying Flow
Rapidly Varying Flow
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Composition of Blood Plasma

